Mr. William Jackson reports

VECTOR SCIENCE AND THERAPEUTICS CORP. (TSXV: PAIN) FILES PROVISIONAL PATENT APPLICATION ON INTEGRATED PLATFORM FOR ORTHOPEDIC TISSUE REGENERATION USING PEPTIDES

Vector Science and Therapeutics Corp. has filed a provisional patent application with the United States Patent and Trademark Office covering an integrated platform intended to improve tissue healing across orthopedic surgical care.

The application describes compositions, systems and methods that pair tissue-repair-promoting peptides with a patient's own platelet-rich plasma or platelet-rich fibrin. Vector believes the combination has the potential, subject to further preclinical and clinical development, to produce a regenerative response greater than what either element contributes on its own.

The application also describes adjunct formulations addressing a problem Vector believes has gone largely unaddressed. Several agents used routinely in orthopedic surgery for pain control and infection prevention have been reported in the published literature to work against the very cells and processes a regenerative therapy depends on. The filing covers approaches formulated and sequenced specifically to reduce that conflict.

"My background is in orthopedic and reconstructive orthopedic sales, so I'm particularly excited about this filing," said William Jackson, chief executive officer of Vector. "These peptides were reclassified out of FDA's higher-risk compounding category earlier this year, and a federal advisory committee has since recommended several for inclusion on the agency's approved compounding list. More than 30 million Americans suffer from osteoarthritis. Orthopedic and sports medicine surgeons have used platelet-rich biologics for years. What has been missing is a way to bring those biologics together with regenerative peptides, and to keep the rest of the surgical protocol from undoing the benefit. That co-ordination is what this filing is about."

The provisional application establishes a priority date and gives Vector a 12-month window in which to pursue a non-provisional filing. The platform is in the development stage. All candidates described are investigational and have not been approved for any indication by the U.S. Food and Drug Administration or any other regulatory body. No clinical studies have been conducted, and nothing in this release should be understood as a claim of safety or efficacy in humans. Vector is not disclosing specific formulations, dosing ranges or system design details at this time.

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics is a medical technology company advancing drug delivery technology and peptide manufacturing for the sports medicine, regenerative medicine, and pain management markets. The company's intellectual property portfolio spans advanced transdermal delivery, precision catheter systems, localized pain management, regenerative medicine, pancreatic oncology, smart wound care, lyophilized pharmaceutical systems and next-generation therapeutic delivery. Vector is headquartered in Mequon, Wis.

We seek Safe Harbor.